

- and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. *Br J Haematol*. 2011;154(3):387–397.
- Vichinsky E, Styles L. Pulmonary complications. *Hematol Oncol Clin North Am*. 1996;10(6):1275–1286.
- Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolong administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year single-center trial (LaSHS). *Blood*. 2010;115(12):2354–2363.
- Walsh CE, Batt KM. Hemophilia clinical gene therapy: brief review. *Transl Res*. 2013;161(4):307–312.
- Wang B, Zhan S, Gong T, et al. Iron therapy for improving psychomotor development and cognitive function in children under the age of three with iron deficiency anemia. *Cochrane Database Syst Rev*. 2013;(6) [CD001444].
- Wang WC, Dwan K. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. *Cochrane Database Syst Rev*. 2013;(11) [CD003146].
- Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicenter, randomised, controlled trial (BABY HUG). *Lancet*. 2011;377(9778):1663–1672.
- Wilson DB. Acquired platelet defects. Orkin SH, Nathan DG, Ginsburg D, et al. *Nathan and Oski's hematology of infancy and childhood*. ed 7. Saunders: Philadelphia; 2009.
- Yaish HM. *Pediatric thalassemia*.
<http://emedicine.medscape.com/article/958850-overview>;
 2015.
- Yawn BP, Buchanan GR, Afeniyi-Annan AN, et al. Management of sickle cell disease summary of the 2014 evidence-based report by expert panel members. *JAMA*. 2014;312(10):1033–1048.
- Yogev R, Chadwick EG. Acquired immunodeficiency syndrome (human immunodeficiency virus). Kliegman RM, Jenson HB, Behrman RE, et al. *Nelson textbook of pediatrics*. ed 19. Saunders/Elsevier: Philadelphia; 2011.
- Ziegler EE. Consumption of cow's milk as a cause of iron deficiency in infants and toddlers. *Nutr Rev*. 2011;69(Suppl